Using NK cells isolated from CD34+ cord blood cells for AML patients who received initial chemotherapy regimen and not eligible to HSCT was not associated with GVHD, severe infections or symptoms of cytokine release syndrome [21]. This evidence concerns the gene CD34 and graft versus host disease.